Simulations Plus, Inc. (NASDAQ:SLP) Given Average Rating of “Buy” by Analysts

Simulations Plus, Inc. (NASDAQ:SLP) has earned an average recommendation of “Buy” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $50.00.

A number of brokerages recently commented on SLP. KeyCorp raised their price target on Simulations Plus from $32.00 to $40.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 16th. StockNews.com raised Simulations Plus from a “sell” rating to a “hold” rating in a research note on Monday, April 28th.

Insider Buying and Selling

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $33.51, for a total value of $670,200.00. Following the completion of the transaction, the director now owns 3,344,157 shares in the company, valued at approximately $112,062,701.07. This represents a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 19.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Simulations Plus

A number of institutional investors have recently added to or reduced their stakes in the company. Woodline Partners LP raised its holdings in Simulations Plus by 32.1% in the first quarter. Woodline Partners LP now owns 13,239 shares of the technology company’s stock worth $325,000 after purchasing an additional 3,220 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Simulations Plus in the first quarter worth $255,000. Uniplan Investment Counsel Inc. raised its holdings in Simulations Plus by 141.8% in the first quarter. Uniplan Investment Counsel Inc. now owns 144,202 shares of the technology company’s stock worth $3,536,000 after purchasing an additional 84,562 shares in the last quarter. NFJ Investment Group LLC bought a new position in Simulations Plus in the first quarter worth $1,254,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Simulations Plus by 4.3% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,493 shares of the technology company’s stock worth $233,000 after purchasing an additional 390 shares in the last quarter. Institutional investors own 78.08% of the company’s stock.

Simulations Plus Stock Performance

NASDAQ:SLP opened at $31.53 on Monday. The firm has a market cap of $634.10 million, a PE ratio of 78.83 and a beta of 1.10. Simulations Plus has a fifty-two week low of $23.01 and a fifty-two week high of $50.98. The business has a 50 day moving average price of $29.06 and a 200-day moving average price of $30.28.

Simulations Plus (NASDAQ:SLP) last released its quarterly earnings data on Thursday, April 3rd. The technology company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.06. The firm had revenue of $22.43 million during the quarter, compared to analyst estimates of $21.93 million. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The business’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.20 earnings per share. Research analysts predict that Simulations Plus will post 1.09 EPS for the current year.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.